




ASO VISUAL ABSTRACT


## ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease

Miquel Ensenyat-Mendez, MSc<sup>1</sup>, Dennis Runger, PhD<sup>2</sup>, Javier I. J. Orozco, MD<sup>3</sup>, Julie Le, MD<sup>4</sup>, Jennifer L. Baker, MD<sup>4</sup>, Joanne Weidhaas, MD, PhD<sup>5</sup>, Diego M. Marzese, PhD<sup>1</sup>, and Maggie L. DiNome, MD<sup>6</sup> 

<sup>1</sup>Cancer Epigenetics Laboratory at the Cancer Cell Biology Group, Institut d'Investigaci3 Sanitaria Illes Balears (IdISBa), Palma, Spain; <sup>2</sup>Statistics Core, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA; <sup>4</sup>Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>5</sup>Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>6</sup>Department of Surgery, Duke University School of Medicine, Durham, NC

Patients with estrogen-positive, node-positive breast cancer who are not treated with neoadjuvant chemotherapy are recommended axillary lymph node dissection (ALND).

Epigenetic signatures may provide a molecular-based strategy for identifying patients with limited nodal disease who can avoid ALND (<https://doi.org/10.1245/s10434-022-11684-0>).



Diego M. Marzese and Maggie L. DiNome have equally contributed to this work.

**DISCLOSURE** There are no conflicts of interest.

© Society of Surgical Oncology 2022

Published Online: 16 April 2022

M. L. DiNome, MD  
e-mail: Maggie.dinome@duke.edu

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.